Faculty profile
Denys Khaperskyy
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a Dalhousie University directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $1,120,726
Role of Nsp1-mediated general host shutoff in SARS-CoV-2 replication
CIHR · 2026 · Nominated PI
- $150,000
Functional characterization of cross-reactive and specific antibodies against highly-pathogenic avian influenza at human/wildlife interface
CIHR · 2024 · Nominated PI
- $4,569,190
Open-label, phase 1/2, dose-escalation and dose-confirmation clinical trial to establish a Controlled Human Infection Model (CHIM) by determining and confirming the optimal, safe, and reproducible Influenza A:H3N2 dose administered intranasally to healthy adults 18-40 years of age that induces mild symptomatic infection and detection of Influenza A:H3N2 in nasal secretions by culture and/or PCR
CIHR · 2023 · Co-investigator
Role of Nsp1-mediated general host shutoff in SARS-CoV-2 replication
Principal investigators: Khaperskyy, Denys
Keywords: Biochemistry; Molecular Virology; Protein-Rna Interactions; Sars-Cov-2; Viral Host Shutoff
Functional characterization of cross-reactive and specific antibodies against highly-pathogenic avian influenza at human/wildlife interface
Principal investigators: Khaperskyy, Denys
Keywords: Hpai
Open-label, phase 1/2, dose-escalation and dose-confirmation clinical trial to establish a Controlled Human Infection Model (CHIM) by determining and confirming the optimal, safe, and reproducible Influenza A:H3N2 dose administered intranasally to healthy adults 18-40 years of age that induces mild symptomatic infection and detection of Influenza A:H3N2 in nasal secretions by culture and/or PCR
Principal investigators: Halperin, Scott A; Ward, Brian J
Keywords: Challenge Study; Challenge Unit; Controlled Human Infection Model (Chim); Dose-Finding; Dose-Ranging; Healthy Adults; Influenza Virus; Pandemic Preparedness; Phase 1/2 Clinical Trial
Open-label, phase 1/2, dose-escalation and dose-confirmation clinical trial to establish a Controlled Human Infection Model (CHIM) by determining and confirming the optimal, safe, and reproducible Influenza A:H3N2 dose administered intranasally to healthy adults 18-40 years of age that induces mild symptomatic infection and detection of Influenza A:H3N2 in nasal secretions by culture and/or PCR
Principal investigators: Halperin, Scott A; Ward, Brian J
Keywords: Challenge Study; Challenge Unit; Controlled Human Infection Model (Chim); Dose-Finding; Dose-Ranging; Healthy Adults; Influenza Virus; Pandemic Preparedness; Phase 1/2 Clinical Trial
Molecular mechanisms of host shutoff by respiratory viruses and their contribution to viral pathogenesis
Principal investigators: Khaperskyy, Denys
Keywords: Coronavirus; Host Shutoff; Influenza Virus; Innate Immune Responses; Non-Structural Protein 1 (Ns1); Non-Structural Protein 1 (Nsp1); Polymerase Acidic Protein X (Pa-X); Protein-Protein Interactions
High-throughput single-cell imaging flow cytometry platform
Principal investigators: Cheng, Zhenyu
Functional characterisation of stress granule composition and morphology
Principal investigators: Khaperskyy, Denys
Functional characterisation of stress granule composition and morphology
Principal investigators: Khaperskyy, Denys
Discovery and Preclinical Development of Novel Stress Granule-Inducing Antiviral Drugs
Principal investigators: McCormick, Craig
Keywords: Antiviral Drug; Commercialization; Drug Resistance; Evolution; Influenza; Mechanism Of Action; Rna; Stress Granule; Translation; Virus
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.